CV Sciences (CVSI) Debt Ratio (2013 - 2026)

CV Sciences (CVSI) posted Debt Ratio of 0.01 for Q1 2026, down 95.48% sequentially from 0.24 in Q4 2025, and down 93.44% YoY from 0.16 in Q1 2025.

CV Sciences (CVSI) Debt Ratio (2013 - 2026) Analysis & Trends

CV Sciences has reported Debt Ratio for 11 years, with the latest figure at 0.01 in Q1 2026.

Quarterly Debt Ratio fell 93.44% year-over-year to 0.01 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01 (down 93.44% YoY) and the FY2025 annual result came in at 0.24, up 177.34% from the prior year.
Debt Ratio eased to 0.01 in Q1 2026 per CVSI's latest filing, from 0.24 in the prior quarter.
Over five years, Debt Ratio peaked at 0.24 in Q4 2025 and troughed at 0.01 in Q1 2026.
A 4-year average of 0.13 and a median of 0.14 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2026: Debt Ratio jumped 698.12% in 2022, then sank 93.44% in 2026.
Over 4 years, Debt Ratio stood at 0.14 in 2022, then tumbled by 36.94% to 0.09 in 2024, then jumped by 177.34% to 0.24 in 2025, then tumbled by 95.48% to 0.01 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.01, 0.24, and 0.14 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn	0.42
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn	0.32
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn	-
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	-
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-	0.12
10	CV Sciences	4.10 Mn	3.84 Mn	1.45 Mn	0.00

Download Data